These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 15569618)
1. The L.E.A.P.S. approach to vaccine development. Zimmerman DH; Rosenthal KS Front Biosci; 2005 Jan; 10():790-8. PubMed ID: 15569618 [TBL] [Abstract][Full Text] [Related]
2. Ligand epitope antigen presentation system vaccines against herpes simplex virus. Goel N; Zimmerman DH; Rosenthal KS Front Biosci; 2005 Jan; 10():966-74. PubMed ID: 15569635 [TBL] [Abstract][Full Text] [Related]
3. LEAPS therapeutic vaccines as antigen specific suppressors of inflammation in infectious and autoimmune diseases. Zimmerman DH; Steiner H; Carmabula R; Talor E; Rosenthal KS J Vaccines Vaccin; 2012 Sep; 3(5):. PubMed ID: 23400692 [TBL] [Abstract][Full Text] [Related]
4. A L.E.A.P.S. heteroconjugate vaccine containing a T cell epitope from HSV-1 glycoprotein D elicits Th1 responses and protection. Goel N; Rong Q; Zimmerman D; Rosenthal KS Vaccine; 2003 Oct; 21(27-30):4410-20. PubMed ID: 14505924 [TBL] [Abstract][Full Text] [Related]
5. Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. Berzofsky JA Biotechnol Ther; 1991; 2(1-2):123-35. PubMed ID: 1726961 [TBL] [Abstract][Full Text] [Related]
6. A recombinant single-chain human class II MHC molecule (HLA-DR1) as a covalently linked heterotrimer of alpha chain, beta chain, and antigenic peptide, with immunogenicity in vitro and reduced affinity for bacterial superantigens. Zhu X; Bavari S; Ulrich R; Sadegh-Nasseri S; Ferrone S; McHugh L; Mage M Eur J Immunol; 1997 Aug; 27(8):1933-41. PubMed ID: 9295029 [TBL] [Abstract][Full Text] [Related]
7. Induction of cross clade reactive specific antibodies in mice by conjugates of HGP-30 (peptide analog of HIV-1(SF2) p17) and peptide segments of human beta-2-microglobulin or MHC II beta chain. Zimmerman DH; Lloyd JP; Heisey D; Winship MD; Siwek M; Talor E; Sarin PS Vaccine; 2001 Sep; 19(32):4750-9. PubMed ID: 11535326 [TBL] [Abstract][Full Text] [Related]
8. Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma. Wong R; Lau R; Chang J; Kuus-Reichel T; Brichard V; Bruck C; Weber J Clin Cancer Res; 2004 Aug; 10(15):5004-13. PubMed ID: 15297401 [TBL] [Abstract][Full Text] [Related]
9. Single-chain HLA-A2 MHC trimers that incorporate an immundominant peptide elicit protective T cell immunity against lethal West Nile virus infection. Kim S; Li L; McMurtrey CP; Hildebrand WH; Weidanz JA; Gillanders WE; Diamond MS; Hansen TH J Immunol; 2010 Apr; 184(8):4423-30. PubMed ID: 20212098 [TBL] [Abstract][Full Text] [Related]
10. Ii-Key/MHC class II epitope peptides as helper T cell vaccines for cancer and infectious disease. Kallinteris NL; Powell D; Blackwell CE; Kim M; Lu X; Wu S; Humphreys RE; Xu M; von Hofe E Front Biosci; 2006 Jan; 11():46-58. PubMed ID: 16146713 [TBL] [Abstract][Full Text] [Related]
14. Maturation of dendritic cell precursors into IL12-producing DCs by J-LEAPS immunogens. Taylor PR; Paustian CC; Koski GK; Zimmerman DH; Rosenthal KS Cell Immunol; 2010; 262(1):1-5. PubMed ID: 20163792 [TBL] [Abstract][Full Text] [Related]
15. Peptide vaccines incorporating a 'promiscuous' T-cell epitope bypass certain haplotype restricted immune responses and provide broad spectrum immunogenicity. Kaumaya PT; Kobs-Conrad S; Seo YH; Lee H; VanBuskirk AM; Feng N; Sheridan JF; Stevens V J Mol Recognit; 1993 Jun; 6(2):81-94. PubMed ID: 7508238 [TBL] [Abstract][Full Text] [Related]
16. Immune peptide enhancement of peptide based vaccines. Rosenthal KS Front Biosci; 2005 Jan; 10():478-82. PubMed ID: 15574384 [TBL] [Abstract][Full Text] [Related]
17. Multiple Approaches for Increasing the Immunogenicity of an Epitope-Based Anti-HIV Vaccine. Rosa DS; Ribeiro SP; Fonseca SG; Almeida RR; Santana VC; Apostólico Jde S; Kalil J; Cunha-Neto E AIDS Res Hum Retroviruses; 2015 Nov; 31(11):1077-88. PubMed ID: 26149745 [TBL] [Abstract][Full Text] [Related]
18. MHC-restricted antigen presentation and recognition: constraints on gene, recombinant and peptide vaccines in humans. Cunha-Neto E Braz J Med Biol Res; 1999 Feb; 32(2):199-205. PubMed ID: 10347755 [TBL] [Abstract][Full Text] [Related]
19. [Molecular basis for detection of infectious agents]. Siegrist CA Schweiz Med Wochenschr; 1996 Feb; 126(7):246-54. PubMed ID: 8720322 [TBL] [Abstract][Full Text] [Related]
20. An immunoinformatics-derived DNA vaccine encoding human class II T cell epitopes of Ebola virus, Sudan virus, and Venezuelan equine encephalitis virus is immunogenic in HLA transgenic mice. Bounds CE; Terry FE; Moise L; Hannaman D; Martin WD; De Groot AS; Suschak JJ; Dupuy LC; Schmaljohn CS Hum Vaccin Immunother; 2017 Dec; 13(12):2824-2836. PubMed ID: 28575582 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]